J Rösche1,2, K Kupper3,4, M Wittstock3, U Walter3. 1. Klinik für Neurologie und Poliklinik, Universitätsmedizin Rostock, Gehlsheimer Str. 20, 18147, Rostock, Deutschland. johannes.roesche@kliniklengg.ch. 2. Klinik Lengg AG, Bleulerstr. 60, 8008, Zürich, Schweiz. johannes.roesche@kliniklengg.ch. 3. Klinik für Neurologie und Poliklinik, Universitätsmedizin Rostock, Gehlsheimer Str. 20, 18147, Rostock, Deutschland. 4. Klinikum Altenburger Land GmbH, Am Waldessaum 10, 04600, Altenburg, Deutschland.
Abstract
BACKGROUND AND OBJECTIVES: Nowadays, there is an ongoing discussion about the risks and benefits of anesthetic treatment concerning outcome in status epilepticus (SE). Therefore, we performed a retrospective database analysis to examine the influence of treatment with anesthetic drugs and narcosis in SE on mortality and disability. METHODS: All treatment episodes of SE at the Department of Neurology of the University of Rostock between 01 January 2000 and 31 December 2009 were evaluated. SE severity before treatment, mortality, and disability at discharge were taken into account. RESULTS: Of 167 treatment episodes of SE, 34 included treatment with anesthetic anticonvulsive drugs and narcosis. In the treatment episodes with use of anesthetic anticonvulsive drugs and narcosis, there was a more than twofold increased risk for death compared to the other treatment episodes. However, due to sample size this difference was not significant (p = 0.09). Cardiopulmonary complications were the cause of death in 4 of 5 patients dying during treatment episodes with anesthetic anticonvulsive drugs and narcosis. At discharge, disability as measured with the Modified Rankin Scale was higher in patients treated with anesthetic anticonvulsive drugs and narcosis than in the others (p = 0.03). A subgroup analysis revealed that especially in patients with nonconvulsive SE with impaired consciousness treatment with narcosis was associated with a higher rate of new deficits or mortality (p = 0.012). CONCLUSIONS: Especially when considering narcosis for treatment of nonconvulsive SE, risks and benefits should be carefully weighed. When treating SE with anesthetic drugs and narcosis, everything has to be done to avoid cardiopulmonary complications.
BACKGROUND AND OBJECTIVES: Nowadays, there is an ongoing discussion about the risks and benefits of anesthetic treatment concerning outcome in status epilepticus (SE). Therefore, we performed a retrospective database analysis to examine the influence of treatment with anesthetic drugs and narcosis in SE on mortality and disability. METHODS: All treatment episodes of SE at the Department of Neurology of the University of Rostock between 01 January 2000 and 31 December 2009 were evaluated. SE severity before treatment, mortality, and disability at discharge were taken into account. RESULTS: Of 167 treatment episodes of SE, 34 included treatment with anesthetic anticonvulsive drugs and narcosis. In the treatment episodes with use of anesthetic anticonvulsive drugs and narcosis, there was a more than twofold increased risk for death compared to the other treatment episodes. However, due to sample size this difference was not significant (p = 0.09). Cardiopulmonary complications were the cause of death in 4 of 5 patients dying during treatment episodes with anesthetic anticonvulsive drugs and narcosis. At discharge, disability as measured with the Modified Rankin Scale was higher in patients treated with anesthetic anticonvulsive drugs and narcosis than in the others (p = 0.03). A subgroup analysis revealed that especially in patients with nonconvulsive SE with impaired consciousness treatment with narcosis was associated with a higher rate of new deficits or mortality (p = 0.012). CONCLUSIONS: Especially when considering narcosis for treatment of nonconvulsive SE, risks and benefits should be carefully weighed. When treating SE with anesthetic drugs and narcosis, everything has to be done to avoid cardiopulmonary complications.
Entities:
Keywords:
Cardiopulmonary complications; Narcosis; Status epilepticus
Authors: Robert G Kowalski; Wendy C Ziai; Richard N Rees; J Kent Werner; Grace Kim; Haley Goodwin; Romergryko G Geocadin Journal: Crit Care Med Date: 2012-09 Impact factor: 7.598
Authors: Taher T Vohra; Joseph B Miller; Katherine S Nicholas; Panayiotis N Varelas; Donna M Harsh; Valerie Durkalski; Robert Silbergleit; Henry E Wang Journal: Neurocrit Care Date: 2015-08 Impact factor: 3.210
Authors: Frederick A Zeiler; Kaitlin J Zeiler; Jeanne Teitelbaum; Lawrence M Gillman; Michael West Journal: Can J Neurol Sci Date: 2015-07 Impact factor: 2.104
Authors: Andrea O Rossetti; Giancarlo Logroscino; Tracey A Milligan; Costas Michaelides; Christiane Ruffieux; Edward B Bromfield Journal: J Neurol Date: 2008-09-03 Impact factor: 4.849
Authors: Eugen Trinka; Hannah Cock; Dale Hesdorffer; Andrea O Rossetti; Ingrid E Scheffer; Shlomo Shinnar; Simon Shorvon; Daniel H Lowenstein Journal: Epilepsia Date: 2015-09-04 Impact factor: 5.864
Authors: Alexander B Ramos; Roberto A Cruz; Nicole R Villemarette-Pittman; Piotr W Olejniczak; Edward C Mader Journal: J Investig Med High Impact Case Rep Date: 2019 Jan-Dec